Cancer treatment and research communications最新文献

{"title":"Complete response of unilateral primary lacrimal sac diffuse large B-cell lymphoma treated without radiotherapy in an adult: A rare case report and review of the literature","authors":"Suzana Sultan ,&nbsp;Tasnim Ibrahim ,&nbsp;Ali Habib ,&nbsp;Firas Hussein","doi":"10.1016/j.ctarc.2025.100897","DOIUrl":"10.1016/j.ctarc.2025.100897","url":null,"abstract":"<div><div>Diffuse large B-cell lymphoma (DLBCL) manifests extranodally in one-third of non-Hodgkin lymphoma (NHL) cases. However, primary DLBCL of the lacrimal sac is very rare. A 54-year-old man presented with a 5-month history of right-sided epiphora. He visited three private clinics and was misdiagnosed with conjunctivitis. Later, a painless mass in the right lacrimal area prompted an MRI scan followed by a CT scan, which suggested a lacrimal sac mass. The mass was surgically excised, and histopathology and immunohistochemistry revealed DLBCL. A PET/CT scan was done instead of bone marrow biopsy, which excluded systemic lymphomatous involvement, confirming the diagnosis of primary right lacrimal sac DLBCL. The patient received six standard cycles of the R-CHOP regimen. Although no radiotherapy was used, CT findings after the completion of the 4th cycle showed a complete response (CR), which was maintained in a follow-up CT scan 2 months after chemotherapy completion. Despite the rarity of the tumor, it should be considered in the differential diagnosis of long-standing or unresponsive inflammatory conditions. Radiotherapy-free management could achieve CR in limited-stage DLBCL.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100897"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143642646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ezetimibe mediated RPS6KA2 inhibits colorectal cancer proliferation via PCSK9/MAPK signaling pathway","authors":"Yu Wang ,&nbsp;Yuting Wang ,&nbsp;Huabin Gao ,&nbsp;Lin Chen,&nbsp;Shuai Zheng,&nbsp;Yongyu Chen,&nbsp;Huijuan Shi,&nbsp;Anjia Han","doi":"10.1016/j.ctarc.2025.100899","DOIUrl":"10.1016/j.ctarc.2025.100899","url":null,"abstract":"<div><div>To investigate the effect and molecular mechanism of ezetimibe on colorectal cancer (CRC), our study found that ezetimibe significantly inhibited the proliferation and progression of CRC. Further study showed that RPS6KA2 might be the target gene of ezetimibe treatment on CRC. RPS6KA2 expression was significantly lower in human CRC tissue samples and associated with T classification and vascular invasion of tumor cells. RPS6KA2 inhibited proliferation, migration, and invasion of CRC cells. The underlying mechanisms indicated that interaction between RPS6KA2 and PCSK9 was observed within the cytoplasmic compartment of CRC cells. RPS6KA2 suppressed PCSK9 and MAPK signaling pathway in CRC cells. BI-D1780 which is an inhibitor of RPS6KA2 increased PCSK9 and MAPK signaling pathway related proteins expression in SW620 cells. However, an inhibitor or stimulator of MAPK did not affect RPS6KA2 and PCSK9 expression, respectively. In vivo, CRC cells with RPS6KA2 or PCSK9 overexpression could inhibit or promote tumor growth and metastasis, respectively. PCSK9 promoted proliferation, migration, and invasion of CRC cells. PCSK9 expression was higher in human CRC samples and associated with N classification and TNM stage of CRC. In conclusion, our study firstly suggests that ezetimibe suppresses CRC progression by upregulating RPS6KA2 while downregulating PCSK9/MAPK signaling pathway.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100899"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143668762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systemic review on chemotherapy induced nausea and vomiting- risk and clinical management with alternative therapies","authors":"Derangula Lavanya ,&nbsp;VelugotlaPranathi Prasanna ,&nbsp;Asma Firdous ,&nbsp;Sneha Thakur","doi":"10.1016/j.ctarc.2025.100938","DOIUrl":"10.1016/j.ctarc.2025.100938","url":null,"abstract":"<div><div>Chemotherapy-induced nausea and vomiting (CINV) affects up to 80 % of cancer patients, significantly impacts the health in terms of their quality of life and straining healthcare resources. CINV is categorized into anticipatory, acute, and delayed types. Risk factors include younger age, female sex, a history of CINV, and the emetogenic potential of the chemotherapy agents. Drugs like cisplatin and anthracycline-cyclophosphamide combinations are highly emetogenic and pose the greatest risk. Advances in managing CINV include evidence-based guidelines and the use of antiemetic medications such as 5-HT3 receptor antagonists, NK-1 receptor antagonists, and corticosteroids. These measures have reduced vomiting incidents, but complete control of nausea remains challenging. Up to 60 % of patients still experience delayed nausea, and anticipatory nausea and vomiting affect up to 30 % and 20 % of patients, respectively, by the fourth treatment cycle. Clinical and alternative therapies are though effective, research suggests integrated management for CINV. Tailored approach is needed as it has both psychological and physiological influence. To overcome the challenges, the guidelines and antiemetic regimens should be improved according to individual patient evaluation and awareness is necessary. Research is ongoing to develop targeted therapies that combine pharmacological and behavioral interventions to improve CINV management, especially for patients who do not respond well to current antiemetic treatments.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100938"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144178815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The utility of immunohistochemistry-based biomarkers in predicting the pathological complete response in early-stage triple-negative breast cancer","authors":"Chikako Funasaka ,&nbsp;Takahiro Kogawa ,&nbsp;Naoya Sakamoto ,&nbsp;Shota Kusuhara ,&nbsp;Takehiro Nakao ,&nbsp;Hiromichi Nakajima ,&nbsp;Chihiro Kondoh ,&nbsp;Kenichi Harano ,&nbsp;Nobuaki Matsubara ,&nbsp;Ako Hosono ,&nbsp;Yoichi Naito ,&nbsp;Mototsugu Shimokawa ,&nbsp;Rurina Watanuki ,&nbsp;Yuji Yamashita ,&nbsp;Chisako Yamauchi ,&nbsp;Tatsuya Onishi ,&nbsp;Genichiro Ishii ,&nbsp;Toru Mukohara","doi":"10.1016/j.ctarc.2025.100941","DOIUrl":"10.1016/j.ctarc.2025.100941","url":null,"abstract":"<div><div>Triple-negative breast cancer (TNBC) is a highly aggressive subtype of BC. A pathological complete response (pCR) to neoadjuvant chemotherapy is strongly associated with a favorable TNBC prognosis; however, established predictors of pCR, including tumor-infiltrating lymphocytes (TILs), are often not adequately reliable in the clinic. This study evaluated the utility of immunohistochemistry (IHC)-based markers and TILs in predicting pCR in early-stage TNBC. This study enrolled 61 women with stage I–III TNBC who were treated at our institution between January 2013 and December 2019. Pathological data were collected from electronic medical records, while IHC data were obtained from preoperative biopsy specimens. Fisher’s test, multivariable logistic regression, and correlation analyses were used to identify biomarker candidates and their interactions. The majority of the patients had stage II or III invasive ductal TNBC. The pCR rate was 31 % (19/61). High TIL frequencies (≥ 40 %) and high Ki-67 (≥ 40 %) levels were associated with pCR. Among the patients with high TIL frequencies, AR-negative patients had a higher pCR rate than AR-positive patients (55.0 % versus 16.7 %; <em>p</em> = 0.71). Vimentin negativity correlated with high TIL frequencies (<em>p</em> = 0.02). High TIL frequencies and high Ki-67 levels were independently associated with an increased likelihood of achieving a pCR. The combination of high TIL frequencies and high Ki-67 levels was predictive of pCR in patients with primary TNBC, while AR and vimentin represent candidate markers that require further validation. Further studies should evaluate the performance of these markers in combination with other biomarkers and in the context of immune-checkpoint blockade.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100941"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting lipid metabolism to overcome tamoxifen resistance in breast cancer: Evaluating the synergistic therapeutic potential of quercetin","authors":"Radwa M. Rifaat,&nbsp;Marwa W. Kamel,&nbsp;Marwa Sharaky,&nbsp;Yasmin M. Attia,&nbsp;Samia A. Shouman","doi":"10.1016/j.ctarc.2025.100953","DOIUrl":"10.1016/j.ctarc.2025.100953","url":null,"abstract":"<div><div>Breast cancer remains the most prevalent malignancy among women globally, with hormone receptor-positive subtypes representing the majority of cases. Despite significant advances in treatment, resistance to Tamoxifen, a cornerstone therapy for estrogen receptor-positive (ER⁺) breast cancer, poses a critical challenge, affecting up to 50 % of patients. Emerging evidence suggests that dysregulated lipid metabolism plays a pivotal role in breast cancer progression and therapy resistance. This systematic review aims to explore the intricate relationship between lipid metabolism and Tamoxifen resistance, with a particular focus on the potential therapeutic synergy of combining Tamoxifen with lipid metabolism modulators, such as Quercetin. We systematically searched PubMed, Scopus, Web of Science, and the Cochrane Library for studies published between 2000 and 2023, examining the role of lipid metabolic pathways in breast cancer and the impact of Quercetin on enhancing Tamoxifen efficacy. The findings suggest that targeting key enzymes involved in lipid metabolism, including fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACC), may impair cancer cell survival mechanisms and sensitize tumors to Tamoxifen. The combination of Tamoxifen and Quercetin appears to exhibit synergistic effects, enhancing apoptosis and reducing cell proliferation more effectively than either agent alone. This review highlights the potential of combining Tamoxifen with Quercetin as a therapeutic strategy to overcome Tamoxifen resistance, providing a rationale for further clinical trials to investigate this combination therapy.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100953"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics, incidence, and survival of unknown stage cancer: A US population-based study","authors":"Ray M. Merrill,&nbsp;Alida J. Johnson","doi":"10.1016/j.ctarc.2025.100949","DOIUrl":"10.1016/j.ctarc.2025.100949","url":null,"abstract":"<div><h3>Introduction</h3><div>This study examines the extent of unknown stage cancer incidence for 24 cancer sites in the U.S. based on reporting source, selected variables, and cancer lethality.</div></div><div><h3>Methods</h3><div>Analyses included 5,447,023 malignant cancer cases diagnosed during 2015–2021, collected by 22 population-based cancer registries in the Surveillance, Epidemiology, and End Results (SEER) Program. Poisson regression estimated adjusted rate ratios.</div></div><div><h3>Results</h3><div>Approximately 9.4 % of males and 7.2 % of females had unstaged cancer, significantly varying by reporting source. Levels of unstaged cancer identified by hospital, physician, or other; autopsy; death certificate; or nursing/convalescent home/hospice were 7.8 %, 32.6 %, 97.0 %, and 82.0 % in males and 5.8 %, 31.2 %, 97.1 %, and 82.4 % in females, respectively. Rates increased with age when the reporting source was hospital, physician, or other but decreased with age for autopsy, death certificate, or nursing/convalescence home/hospice. Unstaged cancer rates were similar between men and women (<em>r</em> = 0.93, <em>p</em> &lt; 0.0001, not including breast cancer). However, men were seen to have a 60 % higher rate of unstaged cancer (95 % CI 59 %-61 %) compared to women. Rates increased with age, decreased with income, and were 11 % (95 % CI 10 %-12 %) higher in Blacks (vs. Whites), and 11 % (95 % CI 10 %-12 %) higher in Hispanics (vs. non-Hispanics). A significant negative association was found between unstaged cancer percentages and 5-year relative survival rates for both sexes.</div></div><div><h3>Conclusions</h3><div>Males, older age, Blacks, Hispanics, and lower income patients are more susceptible to not receiving a cancer stage because of higher comorbid illness, more aggressive cancer, and less ability to pay for treatment.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100949"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144196427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of Image-guided Tru-cut biopsy in the diagnosis of breast tumors","authors":"Alya A. Al Zobair ,&nbsp;Wahda M. Al-Nauimy ,&nbsp;Sabruldeen M. Mohammed","doi":"10.1016/j.ctarc.2025.100955","DOIUrl":"10.1016/j.ctarc.2025.100955","url":null,"abstract":"<div><h3>Background</h3><div>Histopathological examination is the gold standard for the diagnosis of breast cancer. This study aims to ascertain the extent to which image-guided Tru-cut biopsy is sensitive and accurate in the diagnosis of breast cancer cases in our locality.</div></div><div><h3>Method</h3><div>This prospective study included 115 patients who presented with one or more breast lumps and suspected to be neoplastic based on the clinical and radiological assessment. All patients have been subjected to Tru-cut biopsy under ultrasound guidance to confirm or exclude the diagnosis of breast tumor, the study was conducted between January 2022 and January 2024</div></div><div><h3>Result</h3><div>Tru-cut biopsy under ultrasound-guidance has shown a high sensitivity and specificity, 98 % and 100 % respectively. Breast carcinoma was confirmed in 106 cases, while benign breast lesions were diagnosed in the remaining nine cases.</div></div><div><h3>Conclusion</h3><div>A Tru-cut biopsy of palpable breast tumors yields comprehensive information with a high sensitivity and specificity, making it a highly reliable diagnostic tool for breast tumors.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100955"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144331121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of hypoxia on extracellular vesicles in malignant and non-malignant conditions","authors":"Vahid Niazi ,&nbsp;Soudeh Ghafouri-Fard","doi":"10.1016/j.ctarc.2025.100924","DOIUrl":"10.1016/j.ctarc.2025.100924","url":null,"abstract":"<div><div>Extracellular vesicles (EVs) are produced by virtually all types of cells and can be detected in nearly all extracellular places. These particles mediate intercellular communication and transfer their cargo to the recipient cells, inducing a variety of processes in these cells through transmission of several biomolecules such as miRNAs, lncRNAs, other transcripts and a variety of proteins. It has been documented that size, quantity, and expression of biomolecules in the EVs are influenced by the level of oxygen. In fact, hypoxia can affect several cellular processes through modulation of the cargo of these vesicles. Hypoxic exosomes derived from tumor cells have several protumoral effects on the recipient cells, including enhancement of proliferation, migration, and invasion in other tumoral cells, induction of metastasis in distant organs, stimulation of angiogenesis in the endothelial cells, and modulation of macrophage polarization. Hypoxic EVs also contribute to several non-malignant diseases. This review summarizes the effect of hypoxia on EVs cargo in malignant and nonmalignant diseases of different organs.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100924"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143799159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"At-home autologous hematopoietic cell transplant for adults with hematological malignancies. How frailty impacts and evolves during HCT procedure. An observational, longitudinal, and prospective study","authors":"Juan Ortiz ,&nbsp;María Teresa Solano ,&nbsp;Cristina Gallego ,&nbsp;Nuria Ballestar ,&nbsp;Noemi de Llobet ,&nbsp;Laia Guardia ,&nbsp;Raquel Salinas ,&nbsp;Alexandra Martínez-Roca ,&nbsp;Beatriz Merchán ,&nbsp;Paola Charry ,&nbsp;Joan Cid ,&nbsp;Miquel Lozano ,&nbsp;Enric Carreras ,&nbsp;Sara Laxe ,&nbsp;Concepción Closa ,&nbsp;María Suárez-Lledó ,&nbsp;Laura Rosiñol ,&nbsp;Carmen Martínez ,&nbsp;Montserrat Rovira ,&nbsp;Francesc Fernández-Avilés ,&nbsp;María Queralt Salas","doi":"10.1016/j.ctarc.2025.100920","DOIUrl":"10.1016/j.ctarc.2025.100920","url":null,"abstract":"<div><h3>Introduction and aims</h3><div>Since April 2021, the frailty state of patients is evaluated routinely in adults undergoing auto-HCT at our institution using the HCT Frailty Scale. The scale categorises each candidate as either fit, pre-fit or frail.</div></div><div><h3>Methods</h3><div>Our study includes 80 consecutive adults with lymphoprolipherative disorders (LPD) and multiple myeloma (MM) undergoing at-home auto-HCT at our institution between June 2021 and June 2023. An initial evaluation of frailty was conducted at first consultation (pre-apheresis), followed by a subsequent evaluation at day +100.</div></div><div><h3>Results</h3><div>The median age was 58 years (range: 19–69), 41 (51.2 %) patients were males, 45 (56.3 %) were diagnosed with MM and 35 with LPD. At the initial consultation, 24 (30.0 %) adults were classified as fit, 48 (60.0 %) as pre-frail, and 8 (10.0 %) as frail. Frail patients were more likely to be older (OR 1.16 <em>P</em> = 0.077), and to have a KPS &lt; 90 % (OR 27, <em>P</em> = 0.012), and also exhibit a higher number of comorbidities (HCT-CI&gt;3: OR 11.9, <em>p</em> = 0.035). However, the underlying diagnosis did not impact the incidence of frailty at the initial consultation (OR 0.99, <em>p</em> = 0.999).</div></div><div><h3>Conclusions</h3><div>There was no association between the duration of at-home transplant hospitalisation and readmissions and the presence of frailty syndrome. Moreover, no patient died due to transplant-related toxicity. The results presented in this study support that at-home auto-HCT can be performed in fit, pre-frail, and frail adults with an experienced and multidisciplinary team. Although conclusions are limited by the reduced sample size, the observed differences on frailty incidences during patient's follow-up support that frailty is dynamic, and potentially amendable with specific interventions.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100920"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143816380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045","authors":"Anke Richters ,&nbsp;Britt Suelmann ,&nbsp;Mira Franken ,&nbsp;Niven Mehra ,&nbsp;Bart Rikhof ,&nbsp;Hans Westgeest ,&nbsp;Katja Aben ,&nbsp;Debbie Robbrecht","doi":"10.1016/j.ctarc.2025.100931","DOIUrl":"10.1016/j.ctarc.2025.100931","url":null,"abstract":"<div><h3>Background and objective</h3><div>Pending adoption of enfortumab-vedotin plus pembrolizumab in first-line setting, platinum-based chemotherapy remains the standard of care for patients with metastatic or locally advanced urothelial cancer (mUC). Second-line pembrolizumab may be offered to patients with disease progression, based on the KEYNOTE-045 trial. It is unclear how well the findings from KEYNOTE-045 translate to the Dutch mUC patient population in routine clinical practice. The objective of this study was to compare characteristics and outcomes of patients in a nationwide population-based pembrolizumab-treated cohort with the KEYNOTE-045 trial.</div></div><div><h3>Methods</h3><div>A contemporary cohort including all patients diagnosed with synchronous mUC of the bladder from January 2018 - June 2023, treated with platinum-based chemotherapy and subsequent pembrolizumab, was identified from the nationwide Netherlands Cancer Registry and Prospective Bladder Cancer Infrastructure, and compared to the KEYNOTE-045 pembrolizumab (KN-P) arm.</div></div><div><h3>Key findings</h3><div>The Dutch cohort included 249 patients; the full KN-P arm included 270 patients (no overlapping patients). The Dutch cohort comprised more patients with ECOG≥2 (10.3% vs 1.1%), hemoglobin levels &lt;10g/dL (29.8% vs 16.4%), and carboplatin-based chemotherapy (49.0% vs 25.9%). At least 24.5% of patients in the Dutch cohort were KEYNOTE-045 ineligible. Median pembrolizumab duration and overall survival were 2.5 (range &lt;0.1-35.6) and 5.5 months (95%CI: 4.4-7.3) in the Dutch cohort, versus 3.5 (&lt;0.1-20.0) and 10.1 months (95%CI: 8.0-12.3) in the KN-P arm.</div></div><div><h3>Conclusion</h3><div>This nationwide cohort demonstrated considerable differences in patient, disease and treatment characteristics as compared to patients in the KN-P arm, with generally less favorable prognostic characteristics and worse survival. Sensitivity analyses on patients with metachronous mUC or mUC of the upper urinary tract did not alter the findings. These findings highlight the importance of adequate patient selection according to the KEYNOTE-045 criteria while also accounting for disparities between patient populations in routine clinical practice and those in clinical trials.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100931"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143844759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}